首页 > 最新文献

Current Opinion in Ophthalmology最新文献

英文 中文
Online intraocular lens calculation. 在线人工晶状体计算。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2024-01-01 Epub Date: 2023-11-03 DOI: 10.1097/ICU.0000000000001014
Dante Buonsanti, Miguel Raimundo, Oliver Findl

Purpose of review: To showcase the majority of online intraocular lens (IOL) calculation tools and highlight some of their characteristics.

Recent findings: Online tools are available for preoperative and postoperative IOL-related calculations, including IOL power and toricity selection for standard patients, patients who underwent prior refractive surgery, keratoconus, limbal relaxing incisions for astigmatism management, realignment of a misplaced or rotated toric IOL, surgical induced astigmatism (SIA), formulae comparison, and other tools.

Summary: As there are new online developments and technology is advancing rapidly, we hope that this review will assist ophthalmologists in becoming acquainted with a large variety of online tools.

综述目的:展示大多数在线人工晶状体(IOL)计算工具,并突出其一些特点。最近的发现:在线工具可用于术前和术后IOL相关的计算,包括标准患者、既往接受屈光手术的患者、圆锥角膜、角膜缘松弛切口用于散光管理、错位或旋转复曲面IOL的调整、手术诱导散光(SIA)、公式比较,以及其他工具。摘要:随着新的在线发展和技术的快速发展,我们希望这篇综述将有助于眼科医生熟悉各种在线工具。
{"title":"Online intraocular lens calculation.","authors":"Dante Buonsanti, Miguel Raimundo, Oliver Findl","doi":"10.1097/ICU.0000000000001014","DOIUrl":"10.1097/ICU.0000000000001014","url":null,"abstract":"<p><strong>Purpose of review: </strong>To showcase the majority of online intraocular lens (IOL) calculation tools and highlight some of their characteristics.</p><p><strong>Recent findings: </strong>Online tools are available for preoperative and postoperative IOL-related calculations, including IOL power and toricity selection for standard patients, patients who underwent prior refractive surgery, keratoconus, limbal relaxing incisions for astigmatism management, realignment of a misplaced or rotated toric IOL, surgical induced astigmatism (SIA), formulae comparison, and other tools.</p><p><strong>Summary: </strong>As there are new online developments and technology is advancing rapidly, we hope that this review will assist ophthalmologists in becoming acquainted with a large variety of online tools.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71434827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immediately sequential bilateral cataract surgery. 立即连续进行双侧白内障手术。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2024-01-01 Epub Date: 2023-10-19 DOI: 10.1097/ICU.0000000000001003
Ali Nowrouzi, Jorge L Alió

Purpose of review: This review aims to clarify the advantages and disadvantages of immediately sequential bilateral cataract surgery (ISBCS) based on recent studies, illustrate the safety of this approach, the cost-effectiveness, and present the importance of inclusion protocols for the best results.

Recent findings: In recent studies, the authors found no evidence of an increased risk of bilateral devastating complications such as endophthalmitis with ISBCS based on descriptive evidence compared to delayed sequential bilateral cataract surgery (DSBCS). Furthermore, recent studies on cost analyses showed that ISBCS resulted in fewer costs and significant cost savings to third-party payers, patients, and society compared to DSBCS.

Summary: The ISBCS surgical approach decreases hospital visits, reduces costs, and provides rapid visual rehabilitation and neuro adaptation. The risk of bilateral simultaneous complications is now recognized to be very rare with intracameral antibiotics and compliance with correct protocols. With new generations of optical biometry and lens calculation formulas, refractive surprises are occasional for normal eyes. However, refractive surprise is controversial, especially in the implantation of presbyopia correction intra-ocular lenses, which must be evaluated carefully in the ISBCS approach.

综述目的:本综述旨在根据最近的研究阐明立即序贯双侧白内障手术(ISBCS)的优缺点,说明这种方法的安全性和成本效益,并介绍纳入方案对获得最佳效果的重要性:在最近的研究中,作者根据描述性证据发现,与延迟顺序双侧白内障手术(DSBCS)相比,ISBCS 没有证据表明双侧破坏性并发症(如眼底炎)的风险会增加。此外,最近的成本分析研究表明,与 DSBCS 相比,ISBCS 的成本更低,为第三方付款人、患者和社会节约了大量成本。摘要:ISBCS 手术方法可减少住院次数,降低成本,并提供快速的视觉康复和神经适应。现在,人们已经认识到,如果使用巩膜内抗生素并遵守正确的操作规程,双侧同时出现并发症的风险是非常罕见的。随着新一代光学生物测量和晶状体计算公式的问世,正常眼睛出现屈光意外的情况已屡见不鲜。然而,屈光意外是有争议的,尤其是在植入老花眼矫正眼内透镜时,必须在 ISBCS 方法中仔细评估。
{"title":"Immediately sequential bilateral cataract surgery.","authors":"Ali Nowrouzi, Jorge L Alió","doi":"10.1097/ICU.0000000000001003","DOIUrl":"10.1097/ICU.0000000000001003","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to clarify the advantages and disadvantages of immediately sequential bilateral cataract surgery (ISBCS) based on recent studies, illustrate the safety of this approach, the cost-effectiveness, and present the importance of inclusion protocols for the best results.</p><p><strong>Recent findings: </strong>In recent studies, the authors found no evidence of an increased risk of bilateral devastating complications such as endophthalmitis with ISBCS based on descriptive evidence compared to delayed sequential bilateral cataract surgery (DSBCS). Furthermore, recent studies on cost analyses showed that ISBCS resulted in fewer costs and significant cost savings to third-party payers, patients, and society compared to DSBCS.</p><p><strong>Summary: </strong>The ISBCS surgical approach decreases hospital visits, reduces costs, and provides rapid visual rehabilitation and neuro adaptation. The risk of bilateral simultaneous complications is now recognized to be very rare with intracameral antibiotics and compliance with correct protocols. With new generations of optical biometry and lens calculation formulas, refractive surprises are occasional for normal eyes. However, refractive surprise is controversial, especially in the implantation of presbyopia correction intra-ocular lenses, which must be evaluated carefully in the ISBCS approach.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxidative stress and antioxidants in cataract development. 白内障发生过程中的氧化应激和抗氧化剂。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2024-01-01 Epub Date: 2023-10-26 DOI: 10.1097/ICU.0000000000001009
Bryanna Lee, Natalie A Afshari, Peter X Shaw

Purpose of review: Oxidative stress plays a central role in cataract pathogenesis, a leading cause of global blindness. This review delves into the role of oxidative stress in cataract development and key biomarkers - glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE) - to clarify their functions and potential applications in predictive diagnostics and therapies.

Recent findings: Antioxidants serve as pivotal markers in cataract pathogenesis. GSH affects the central lens due to factors such as enzyme depletion and altered connexin expression, impairing GSH diffusion. Age-related oxidative stress may hinder GSH transport via connexin channels or an internal microcirculation system. N-acetylcysteine, a GSH precursor, shows promise in mitigating lens opacity when applied topically. Additionally, SOD, particularly SOD1, correlates with increased cataract development and gel formulations have exhibited protective effects against posterior subscapular cataracts. Lastly, markers of lipid peroxidation, MDA and 4-HNE, have been shown to reflect disease severity. Studies suggest a potential link between 4-HNE and connexin channel modification, possibly contributing to reduced GSH levels.

Summary: Oxidative stress is a significant contributor to cataract development, underscoring the importance of antioxidants in diagnosis and treatment. Notably, GSH depletion, SOD decline, and lipid peroxidation markers are pivotal factors in cataract pathogenesis, offering promising avenues for both diagnosis and therapeutic intervention.

综述目的:氧化应激在白内障发病机制中起着核心作用,白内障是导致全球失明的主要原因。这篇综述深入探讨了氧化应激在白内障发展中的作用和关键生物标志物——谷胱甘肽(GSH)、超氧化物歧化酶(SOD)、丙二醛(MDA)和4-羟基壬烯醛(4-HNE)——以阐明它们在预测诊断和治疗中的功能和潜在应用。最近的发现:抗氧化剂是白内障发病机制中的关键标志物。GSH由于酶耗竭和连接蛋白表达改变等因素影响中央晶状体,从而损害GSH的扩散。年龄相关的氧化应激可能阻碍GSH通过连接蛋白通道或内部微循环系统的转运。N-乙酰半胱氨酸是一种谷胱甘肽前体,局部应用时有望减轻晶状体混浊。此外,SOD,特别是SOD1,与白内障发育增加有关,凝胶制剂对肩胛下后叶白内障具有保护作用。最后,脂质过氧化标记物MDA和4-HNE已被证明可以反映疾病的严重程度。研究表明,4-HNE和连接蛋白通道修饰之间存在潜在联系,可能有助于降低GSH水平。摘要:氧化应激是白内障发生的重要因素,强调了抗氧化剂在诊断和治疗中的重要性。值得注意的是,GSH耗竭、SOD下降和脂质过氧化标记物是白内障发病机制的关键因素,为诊断和治疗干预提供了有希望的途径。
{"title":"Oxidative stress and antioxidants in cataract development.","authors":"Bryanna Lee, Natalie A Afshari, Peter X Shaw","doi":"10.1097/ICU.0000000000001009","DOIUrl":"10.1097/ICU.0000000000001009","url":null,"abstract":"<p><strong>Purpose of review: </strong>Oxidative stress plays a central role in cataract pathogenesis, a leading cause of global blindness. This review delves into the role of oxidative stress in cataract development and key biomarkers - glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE) - to clarify their functions and potential applications in predictive diagnostics and therapies.</p><p><strong>Recent findings: </strong>Antioxidants serve as pivotal markers in cataract pathogenesis. GSH affects the central lens due to factors such as enzyme depletion and altered connexin expression, impairing GSH diffusion. Age-related oxidative stress may hinder GSH transport via connexin channels or an internal microcirculation system. N-acetylcysteine, a GSH precursor, shows promise in mitigating lens opacity when applied topically. Additionally, SOD, particularly SOD1, correlates with increased cataract development and gel formulations have exhibited protective effects against posterior subscapular cataracts. Lastly, markers of lipid peroxidation, MDA and 4-HNE, have been shown to reflect disease severity. Studies suggest a potential link between 4-HNE and connexin channel modification, possibly contributing to reduced GSH levels.</p><p><strong>Summary: </strong>Oxidative stress is a significant contributor to cataract development, underscoring the importance of antioxidants in diagnosis and treatment. Notably, GSH depletion, SOD decline, and lipid peroxidation markers are pivotal factors in cataract pathogenesis, offering promising avenues for both diagnosis and therapeutic intervention.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence-based management of optic neuritis. 视神经炎的循证治疗。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2024-01-01 Epub Date: 2023-10-16 DOI: 10.1097/ICU.0000000000001007
Emilie Bergeron, Marc A Bouffard

Purpose of review: Optic neuritis can result from several distinct causes, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD), when not idiopathic. This review discusses evidence-based treatment approaches contingent upon each specific cause of optic neuritis.

Recent findings: Current evidence highlights the need for prompt plasmapheresis as adjunct to intravenous methylprednisolone (IVMP) in patients with NMOSD-associated optic neuritis. Recent advances have included a proliferation of novel disease modifying therapies (DMTs) for long-term management of NMOSD and an understanding of how existing therapeutic options can be leveraged to optimally treat MOGAD.

Summary: In acute idiopathic or MS-associated optic neuritis, IVMP hastens visual recovery, though it does not substantially affect final visual outcomes. IVMP and adjunctive plasmapheresis are beneficial in the treatment of NMOSD-associated optic neuritis, with a shorter time-to-treatment associated with a higher likelihood of recovery. The natural history of untreated MOGAD-associated optic neuritis is unclear but treatment with IVMP is near-universal given phenotypic similarities with NMOSD. Long-term immunosuppressive therapy is warranted in patients with NMOSD as well as in patients with MOGAD with poor visual recovery or recurrent attacks.

综述目的:视神经炎可由几种不同的原因引起,包括多发性硬化症(MS)、视神经脊髓炎谱系障碍(NMOSD)和髓鞘少突胶质细胞糖蛋白抗体疾病(MOGAD),如果不是特发性的。这篇综述讨论了视神经炎的每种特定病因的循证治疗方法。最近的发现:目前的证据强调,在NMOSD相关视神经炎患者中,需要及时进行血浆置换,作为静脉注射甲基强的松龙(IVMP)的辅助手段。最近的进展包括用于NMOSD长期管理的新型疾病修饰疗法(DMTs)的激增,以及对如何利用现有治疗方案来最佳治疗MOGAD的理解。总结:在急性特发性或多发性硬化症相关的视神经炎中,IVMP可加速视觉恢复,但不会对最终视觉结果产生实质性影响。IVMP和辅助血浆置换术有利于治疗NMOSD相关的视神经炎,治疗时间更短,恢复的可能性更高。未经治疗的MOGAD相关视神经炎的自然史尚不清楚,但考虑到与NMOSD的表型相似性,IVMP治疗几乎是普遍的。NMOSD患者以及视觉恢复不良或复发的MOGAD患者需要长期免疫抑制治疗。
{"title":"Evidence-based management of optic neuritis.","authors":"Emilie Bergeron, Marc A Bouffard","doi":"10.1097/ICU.0000000000001007","DOIUrl":"10.1097/ICU.0000000000001007","url":null,"abstract":"<p><strong>Purpose of review: </strong>Optic neuritis can result from several distinct causes, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD), when not idiopathic. This review discusses evidence-based treatment approaches contingent upon each specific cause of optic neuritis.</p><p><strong>Recent findings: </strong>Current evidence highlights the need for prompt plasmapheresis as adjunct to intravenous methylprednisolone (IVMP) in patients with NMOSD-associated optic neuritis. Recent advances have included a proliferation of novel disease modifying therapies (DMTs) for long-term management of NMOSD and an understanding of how existing therapeutic options can be leveraged to optimally treat MOGAD.</p><p><strong>Summary: </strong>In acute idiopathic or MS-associated optic neuritis, IVMP hastens visual recovery, though it does not substantially affect final visual outcomes. IVMP and adjunctive plasmapheresis are beneficial in the treatment of NMOSD-associated optic neuritis, with a shorter time-to-treatment associated with a higher likelihood of recovery. The natural history of untreated MOGAD-associated optic neuritis is unclear but treatment with IVMP is near-universal given phenotypic similarities with NMOSD. Long-term immunosuppressive therapy is warranted in patients with NMOSD as well as in patients with MOGAD with poor visual recovery or recurrent attacks.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41240592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leber hereditary optic neuropathy gene therapy. Leber 遗传性视神经病变基因疗法。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-12-21 DOI: 10.1097/icu.0000000000001028
Byron L Lam
To discuss relevant clinical outcomes, challenges, and future opportunities of gene therapy in Leber hereditary optic neuropathy (LHON).
讨论基因疗法治疗 Leber 遗传性视神经病变 (LHON) 的相关临床结果、挑战和未来机遇。
{"title":"Leber hereditary optic neuropathy gene therapy.","authors":"Byron L Lam","doi":"10.1097/icu.0000000000001028","DOIUrl":"https://doi.org/10.1097/icu.0000000000001028","url":null,"abstract":"To discuss relevant clinical outcomes, challenges, and future opportunities of gene therapy in Leber hereditary optic neuropathy (LHON).","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138826880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genes as drugs for glaucoma: latest advances. 基因作为治疗青光眼的药物:最新进展。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-12-21 DOI: 10.1097/icu.0000000000001025
Teresa Borrás, Michelle Stepankoff, John Danias
To provide the latest advances on the future use of gene therapy for the treatment of glaucoma.
介绍未来使用基因疗法治疗青光眼的最新进展。
{"title":"Genes as drugs for glaucoma: latest advances.","authors":"Teresa Borrás, Michelle Stepankoff, John Danias","doi":"10.1097/icu.0000000000001025","DOIUrl":"https://doi.org/10.1097/icu.0000000000001025","url":null,"abstract":"To provide the latest advances on the future use of gene therapy for the treatment of glaucoma.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138826527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glaucoma surgical procedures under development. 正在开发的青光眼手术程序。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-12-15 DOI: 10.1097/icu.0000000000001020
Ariana M Levin, Arsham Sheybani
Rapid innovation in glaucoma surgery is expanding surgical options in the angle, subconjunctival space, and supraciliary space.
青光眼手术的快速创新扩大了房角、结膜下间隙和睫状上间隙的手术选择范围。
{"title":"Glaucoma surgical procedures under development.","authors":"Ariana M Levin, Arsham Sheybani","doi":"10.1097/icu.0000000000001020","DOIUrl":"https://doi.org/10.1097/icu.0000000000001020","url":null,"abstract":"Rapid innovation in glaucoma surgery is expanding surgical options in the angle, subconjunctival space, and supraciliary space.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138743716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuro-ophthalmic manifestations of Ehlers-Danlos syndrome. 埃勒斯-丹洛斯综合征的神经眼科表现。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-30 DOI: 10.1097/ICU.0000000000001002
Sruti S Rachapudi, Noor A Laylani, Pamela A Davila-Siliezar, Andrew G Lee

Purpose of review: To review the neuro-ophthalmic manifestations of Ehlers-Danlos syndrome (EDS).

Recent findings: Ehlers-Danlos syndrome (EDS) is a rare genetic disorder with an estimated prevalence of 1 in 5000 individuals, but its true prevalence may be underestimated because of variable clinical presentations and limited awareness among healthcare professionals. The neuro-ophthalmic features of EDS may be difficult to recognize in context but new molecular genetic testing is now available for identification of specific subtypes of EDS.

Summary: Ophthalmic manifestations of EDS include loss of vision and double vision (strabismus), high myopia, retinal detachment, and blue sclera. The vascular subtype of EDS can present as a carotid-cavernous fistula, intracranial aneurysm, or arterial dissection.

综述目的:综述埃勒斯-丹洛斯综合征(EDS)的神经眼科表现。最近的研究结果:埃勒斯-达洛斯综合征是一种罕见的遗传性疾病,估计患病率为1/5000,但由于临床表现多变,医疗专业人员的知识有限,其真实患病率可能被低估。EDS的神经眼科特征可能很难在上下文中识别,但新的分子遗传学测试现在可用于识别EDS的特定亚型。总结:EDS的眼科表现包括视力丧失和复视(斜视)、高度近视、视网膜脱离和蓝色巩膜。EDS的血管亚型可表现为颈动脉海绵窦瘘、颅内动脉瘤或动脉夹层。
{"title":"Neuro-ophthalmic manifestations of Ehlers-Danlos syndrome.","authors":"Sruti S Rachapudi,&nbsp;Noor A Laylani,&nbsp;Pamela A Davila-Siliezar,&nbsp;Andrew G Lee","doi":"10.1097/ICU.0000000000001002","DOIUrl":"10.1097/ICU.0000000000001002","url":null,"abstract":"<p><strong>Purpose of review: </strong>To review the neuro-ophthalmic manifestations of Ehlers-Danlos syndrome (EDS).</p><p><strong>Recent findings: </strong>Ehlers-Danlos syndrome (EDS) is a rare genetic disorder with an estimated prevalence of 1 in 5000 individuals, but its true prevalence may be underestimated because of variable clinical presentations and limited awareness among healthcare professionals. The neuro-ophthalmic features of EDS may be difficult to recognize in context but new molecular genetic testing is now available for identification of specific subtypes of EDS.</p><p><strong>Summary: </strong>Ophthalmic manifestations of EDS include loss of vision and double vision (strabismus), high myopia, retinal detachment, and blue sclera. The vascular subtype of EDS can present as a carotid-cavernous fistula, intracranial aneurysm, or arterial dissection.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions 编辑介绍
2区 医学 Q1 Medicine Pub Date : 2023-11-01 DOI: 10.1097/icu.0000000000000993
Current Opinion in Ophthalmology was launched in 1990. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Ophthalmology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Dean CestariDean CestariDr Cestari completed residencies in both Neurology and Ophthalmology at the Cornell University Medical College's New York Presbyterian Hospital, as well as fellowship training in neuro-ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Massachusetts, USA. He is one of approximately 10 physicians in the United States who is board certified by both the American Board of Ophthalmology and the American Board of Psychiatry & Neurology. Dr Cestari joined the full-time faculty of Mass. Eye and Ear, a primary teaching hospital for Harvard Medical School, in 2006 and currently holds the rank of Associate Professor of Ophthalmology, Harvard Medical School. He is very involved in medical education and is the Director of the Clinical Fellowship program at The Massachusetts Eye and Ear Infirmary. His efforts as a clinician-scientist focus on the evaluation and treatment of patients who present with neuro-ophthalmic disease. He is also very involved in the medical and surgical treatment of thyroid eye disease with strabismus and diplopia. He just published a surgical textbook entitled, “Learning Strabismus Surgery, A Case Based Approach.” He supervises clinical fellows, second year residents and visiting medical students and performs adult strabismus surgery and mentors second year residents in the operating theater. Dr Cestari's translational research is focused on developing a rodent model for ischemic optic neuropathy and central retinal artery occlusion. Once this is accomplished, his team will begin to evaluate the safety and efficacy of various novel neuro-protective agents that can be used to preserve and restore vision affected by vascular occlusion. Additionally, he is working with a team of engineers from MIT and Harvard University to design and build an implantable device to restore ocular motility to denervated extra-ocular muscles from nerve palsys. John GonzalesJohn GonzalesDr Gonzales is an Associate Professor of Ophthalmology at the Francis I. Proctor Foundation at the University of California, San Francisco, USA specializing in uveitis and medical cornea. He is supported by an early career award from the National Institutes of Health – National Eye Institute to study the spectrum of keratoconjunctivitis sicca in Sjögren's syndrome utilizing the Sjögren's International Collaborative Clinical Alliance (SICCA) cohort. Dr Gonzales is also pur
《当代眼科意见》创刊于1990年。它是一系列成功的评论期刊之一,其独特的格式旨在提供许多主要期刊中提出的文献的系统和批判性评估。眼科领域分为九个部分,每年审查一次。每个章节都有一个章节编辑,他是该领域的权威,负责确定当时最重要的主题。在这里,我们很高兴地介绍本刊的栏目编辑。Dean Cestari博士在康奈尔大学医学院纽约长老会医院完成了神经病学和眼科的住院医师培训,并在美国马萨诸塞州哈佛医学院马萨诸塞州眼耳医院接受了神经眼科的奖学金培训。他是美国大约10位获得美国眼科委员会和美国精神病学和神经病学委员会认证的医生之一。塞斯塔里博士成为了麻省理工学院的全职教员。眼耳医院是哈佛医学院的主要教学医院,于2006年成立,目前担任哈佛医学院眼科副教授。他非常热衷于医学教育,是马萨诸塞州眼耳医院临床奖学金项目的主任。作为一名临床医生兼科学家,他的工作重点是评估和治疗患有神经眼病的患者。他还积极参与甲状腺眼病伴斜视和复视的内科和外科治疗。他刚刚出版了一本外科教科书,名为《学习斜视手术,基于案例的方法》。他监督临床研究员,二年级住院医师和访问医学生,并进行成人斜视手术,并在手术室指导二年级住院医师。Cestari博士的转化研究重点是开发缺血性视神经病变和视网膜中央动脉闭塞的啮齿动物模型。一旦这项工作完成,他的团队将开始评估各种新型神经保护剂的安全性和有效性,这些保护剂可用于保护和恢复受血管闭塞影响的视力。此外,他正在与来自麻省理工学院和哈佛大学的工程师团队合作,设计并制造一种植入式装置,以恢复神经麻痹的失神经眼外肌的眼球运动。John Gonzales博士是美国加州大学旧金山分校Francis I. Proctor基金会的眼科副教授,专门研究葡萄膜炎和医用角膜。他得到了美国国立卫生研究院国家眼科研究所的早期职业奖的支持,利用Sjögren的国际临床合作联盟(sicca)队列研究Sjögren综合征中干燥性角膜结膜炎的频谱。Gonzales博士也在研究免疫正常个体巨细胞病毒前葡萄膜炎的治疗策略。Gonzales博士的兴趣也扩展到眼部肿瘤学,特别是原发性玻璃体视网膜淋巴瘤,他对临床特征如何与淋巴细胞增殖相关的突变以及对化疗药物的耐药性相关感兴趣。冈萨雷斯博士是《当代眼科学观点》栏目编辑,也是普罗克托基金会葡萄膜炎研究项目主任。
{"title":"Editorial introductions","authors":"","doi":"10.1097/icu.0000000000000993","DOIUrl":"https://doi.org/10.1097/icu.0000000000000993","url":null,"abstract":"Current Opinion in Ophthalmology was launched in 1990. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Ophthalmology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Dean CestariDean CestariDr Cestari completed residencies in both Neurology and Ophthalmology at the Cornell University Medical College's New York Presbyterian Hospital, as well as fellowship training in neuro-ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Massachusetts, USA. He is one of approximately 10 physicians in the United States who is board certified by both the American Board of Ophthalmology and the American Board of Psychiatry & Neurology. Dr Cestari joined the full-time faculty of Mass. Eye and Ear, a primary teaching hospital for Harvard Medical School, in 2006 and currently holds the rank of Associate Professor of Ophthalmology, Harvard Medical School. He is very involved in medical education and is the Director of the Clinical Fellowship program at The Massachusetts Eye and Ear Infirmary. His efforts as a clinician-scientist focus on the evaluation and treatment of patients who present with neuro-ophthalmic disease. He is also very involved in the medical and surgical treatment of thyroid eye disease with strabismus and diplopia. He just published a surgical textbook entitled, “Learning Strabismus Surgery, A Case Based Approach.” He supervises clinical fellows, second year residents and visiting medical students and performs adult strabismus surgery and mentors second year residents in the operating theater. Dr Cestari's translational research is focused on developing a rodent model for ischemic optic neuropathy and central retinal artery occlusion. Once this is accomplished, his team will begin to evaluate the safety and efficacy of various novel neuro-protective agents that can be used to preserve and restore vision affected by vascular occlusion. Additionally, he is working with a team of engineers from MIT and Harvard University to design and build an implantable device to restore ocular motility to denervated extra-ocular muscles from nerve palsys. John GonzalesJohn GonzalesDr Gonzales is an Associate Professor of Ophthalmology at the Francis I. Proctor Foundation at the University of California, San Francisco, USA specializing in uveitis and medical cornea. He is supported by an early career award from the National Institutes of Health – National Eye Institute to study the spectrum of keratoconjunctivitis sicca in Sjögren's syndrome utilizing the Sjögren's International Collaborative Clinical Alliance (SICCA) cohort. Dr Gonzales is also pur","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136371349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ocular features in Williams-Beuren syndrome: a review of the literature. Williams-Beuren综合征的眼部特征:文献综述。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-17 DOI: 10.1097/ICU.0000000000000990
Marco Nassisi, Claudia Mainetti, Andrea Aretti, Andrea Sperti, Valeria Nicotra, Berardo Rinaldi, Federica Natacci, Maria Francesca Bedeschi, Francesco Viola

Purpose of review: The current review will discuss the pathophysiology, work-up and clinical relevance of the ocular phenotype in Williams-Beuren syndrome in detail.

Recent findings: Few case reports, case series and retrospective studies reported the ophthalmic features in Williams-Beuren syndrome, focusing on specific aspects of the ocular involvement. Recently, novel retinal findings have been described in association with the disease.

Summary: Numerous ocular features have been described in Williams-Beuren syndrome. Some of them, such as the stellate pattern of the iris or the retinal arteriolar tortuosity may be helpful for the diagnosis but have no significant clinical implications; others, such as strabismus and refractive errors require early treatment to reduce the risk of irreversible visual impairment. Finally, some features, such as a broad foveal pit and thinner retina still have unknown significance and require further longitudinal and multimodal studies.

综述目的:本综述将详细讨论Williams-Beuren综合征眼部表型的病理生理学、检查和临床相关性。最近的发现:很少有病例报告、病例系列和回顾性研究报道Williams-Beuren综合征的眼科特征,重点是眼部受累的特定方面。最近,新的视网膜发现被描述为与该疾病有关。摘要:Williams-Beuren综合征有许多眼部特征。其中一些,如虹膜的星状图案或视网膜小动脉弯曲可能有助于诊断,但没有显著的临床意义;其他如斜视和屈光不正需要早期治疗,以降低不可逆视觉损伤的风险。最后,一些特征,如宽阔的中央凹和较薄的视网膜,仍然具有未知的意义,需要进一步的纵向和多模式研究。
{"title":"Ocular features in Williams-Beuren syndrome: a review of the literature.","authors":"Marco Nassisi,&nbsp;Claudia Mainetti,&nbsp;Andrea Aretti,&nbsp;Andrea Sperti,&nbsp;Valeria Nicotra,&nbsp;Berardo Rinaldi,&nbsp;Federica Natacci,&nbsp;Maria Francesca Bedeschi,&nbsp;Francesco Viola","doi":"10.1097/ICU.0000000000000990","DOIUrl":"10.1097/ICU.0000000000000990","url":null,"abstract":"<p><strong>Purpose of review: </strong>The current review will discuss the pathophysiology, work-up and clinical relevance of the ocular phenotype in Williams-Beuren syndrome in detail.</p><p><strong>Recent findings: </strong>Few case reports, case series and retrospective studies reported the ophthalmic features in Williams-Beuren syndrome, focusing on specific aspects of the ocular involvement. Recently, novel retinal findings have been described in association with the disease.</p><p><strong>Summary: </strong>Numerous ocular features have been described in Williams-Beuren syndrome. Some of them, such as the stellate pattern of the iris or the retinal arteriolar tortuosity may be helpful for the diagnosis but have no significant clinical implications; others, such as strabismus and refractive errors require early treatment to reduce the risk of irreversible visual impairment. Finally, some features, such as a broad foveal pit and thinner retina still have unknown significance and require further longitudinal and multimodal studies.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10011801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1